Preclinical data suggest a low risk of ADE for potently neutralizing mAbs at doses substantially above the threshold for neutralization, which protected mice and Syrian hamsters against SARS-CoV-2 challenge without enhancement of infection or disease 81,82
1gl), emphasizing the unsuitability of MK-801 monotherapy for obesity treatment
This decentralization has created a patchwork of policies: some states cover GLP-1s for diabetes only, others for both diabetes and obesity, and a few restrict coverage to specific patient populations or BMI thresholds
Cheung W, Keski-Rahkonen P, Assi N, Ferrari P, Freisling H, Rinaldi S, Slimani N, Zamora-Ros R, Rundle M, Frost G, et al
Together, these drugs have transformed how medicine approaches obesity, diabetes and a growing list of other conditions
JAMA 309:23712381 Hughes RO, Bosanac T, Mao X, Engber TM, DiAntonio A, Milbrandt J, Devraj R, Krauss R (2021) Small molecule SARM1 inhibitors recapitulate the SARM1(-/-) phenotype and allow recovery of a metastable pool of axons fated to degenerate
